The association between the COVID-19 infection and venous thromboembolism (VTE) has been observed since first reports from the Chinese population. Specifically, VTE has been associated with the increased mortality of inpatients with COVID-19. Therefore there is a need for clinical information on the incidence and prevalence of VTE in COVID-19 positive patients from different clinical fields in order to better understand the risk of morbidity and mortality. Moreover, a prothrombotic condition has also been detected during this pandemic concerning atherothrombotic manifestations, although it has been less described compared to VTE. Here, atherothrombotic events such as myocardial infarction or ischaemic stroke have been reported in case series or cohorts in a less systematic way compared to VTE.
Antithrombotic treatments during COVID-19 infection are highly debated due to the association with thrombotic diseases. Specifically, anticoagulants and/or antiplatelet agents including therapeutic support seem to be associated with different prognosis when administered in positive patients. Accordingly, based on data concerning the prothrombotic conditions associated with COVID-19 and on the potential role of antithrombotic drugs such as heparin to improve patient prognosis in those affected by COVID-19, it is necessary to explore the clinical experiences on thromboprophylaxis with low molecular weight heparin or other antithrombotic drugs during COVID-19 outbreak.
Considering the aforementioned, this Research Topic aims to address this association between COVID-19 and thrombotic disorders through:
• Original Research investigating the association between COVID-19 and VTE;
• Case reports describing different clinical scenarios in which COVID-19 is associated with thrombotic disorders;
• Reports of clinical experiences of patients with VTE and an objective diagnosis in common or uncommon sites of venous thrombosis;
• Reviews of clinical experiences with antithrombotic treatments or protocols in association with COVID-19;
• Reports of clinical experiences of patients with arterial thrombosis and an objective diagnosis in common situations;
• Reports of clinical experiences of patients with disseminated intravascular coagulation and its management;
The association between the COVID-19 infection and venous thromboembolism (VTE) has been observed since first reports from the Chinese population. Specifically, VTE has been associated with the increased mortality of inpatients with COVID-19. Therefore there is a need for clinical information on the incidence and prevalence of VTE in COVID-19 positive patients from different clinical fields in order to better understand the risk of morbidity and mortality. Moreover, a prothrombotic condition has also been detected during this pandemic concerning atherothrombotic manifestations, although it has been less described compared to VTE. Here, atherothrombotic events such as myocardial infarction or ischaemic stroke have been reported in case series or cohorts in a less systematic way compared to VTE.
Antithrombotic treatments during COVID-19 infection are highly debated due to the association with thrombotic diseases. Specifically, anticoagulants and/or antiplatelet agents including therapeutic support seem to be associated with different prognosis when administered in positive patients. Accordingly, based on data concerning the prothrombotic conditions associated with COVID-19 and on the potential role of antithrombotic drugs such as heparin to improve patient prognosis in those affected by COVID-19, it is necessary to explore the clinical experiences on thromboprophylaxis with low molecular weight heparin or other antithrombotic drugs during COVID-19 outbreak.
Considering the aforementioned, this Research Topic aims to address this association between COVID-19 and thrombotic disorders through:
• Original Research investigating the association between COVID-19 and VTE;
• Case reports describing different clinical scenarios in which COVID-19 is associated with thrombotic disorders;
• Reports of clinical experiences of patients with VTE and an objective diagnosis in common or uncommon sites of venous thrombosis;
• Reviews of clinical experiences with antithrombotic treatments or protocols in association with COVID-19;
• Reports of clinical experiences of patients with arterial thrombosis and an objective diagnosis in common situations;
• Reports of clinical experiences of patients with disseminated intravascular coagulation and its management;
